Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5. https://doi.org/10.1126/science.aar4060.
CAS
Article
PubMed
Google Scholar
Haikal A, Borba E, Khaja T, Doolittle G, Schmidt P. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: a case report and literature review. Avicenna J Med. 2018;8:34–6. https://doi.org/10.4103/ajm.AJM_127_17.
Article
PubMed
PubMed Central
Google Scholar
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91. https://doi.org/10.1093/annonc/mdv383.
CAS
Article
PubMed
PubMed Central
Google Scholar
Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis. 2017;76:1–3. https://doi.org/10.1136/annrheumdis-2016-209782.
CAS
Article
PubMed
Google Scholar
Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.
CAS
Article
Google Scholar
Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–53.
CAS
Article
Google Scholar
Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. https://doi.org/10.1016/j.ctrv.2016.02.003.
CAS
Article
PubMed
Google Scholar
Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. https://doi.org/10.1056/NEJMoa1504030.
CAS
Article
PubMed
PubMed Central
Google Scholar
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. https://doi.org/10.1056/NEJMoa1412082.
CAS
Article
PubMed
Google Scholar
Kwok TSH, Bell MJ. Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis. BMJ Case Rep. 2019;12:e227995. https://doi.org/10.1136/bcr-2018-227995.
Article
PubMed
Google Scholar
Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: a case report. Ann Intern Med. 2016;165:894–5. https://doi.org/10.7326/L16-0137.
Article
PubMed
Google Scholar
Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43–50. https://doi.org/10.1136/annrheumdis-2016-209595.
CAS
Article
PubMed
Google Scholar
Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatic occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50. https://doi.org/10.1136/annrheumdis-2017-211216.
CAS
Article
PubMed
Google Scholar
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RRT, Sullivian MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. https://doi.org/10.1002/art.39480.
Article
PubMed
Google Scholar
Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by check point inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76:2061–4. https://doi.org/10.1136/annrheumdis-2017-211560.
Article
PubMed
Google Scholar